ATL/Interspec merger approved
The merger of ultrasound vendorsATL and Interspec was approved this week by the shareholders ofboth companies. The companies announced the merger in February(SCAN 2/16/94). Under the terms of the merger, Interspec will become a whollyowned subsidiary
The merger of ultrasound vendorsATL and Interspec was approved this week by the shareholders ofboth companies. The companies announced the merger in February(SCAN 2/16/94).
Under the terms of the merger, Interspec will become a whollyowned subsidiary of ATL through an exchange of one share of Interspecstock for 0.413 shares of ATL stock. The acquisition creates anultrasound company with combined revenues of approximately $360million and an installed base of over 20,000 systems.
Interspec chief Edward Ray will continue as president of theAmbler, PA-based company and will join ATL's board of directors.ATL is based in Bothell, WA.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
